T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with Trastuzumab and Pertuzumab

Journal of Clinical Oncology

Volumn 34, Issue 29, 2016, Pages 3511-3517

  Dzimitrowicz, Hannah ^a   Berger, Michael ^b   Vargo, Craig ^b   Hood, Annette ^a   Abdelghany, Osama ^a   Raghavendra, Akshara Singareeka ^c   Tripathy, Debu ^c   Valero, Vicente ^c   Hatzis, Christos ^a   Pusztai, Lajos ^a   Murthy, Rashmi ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERIBULIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IXABEPILONE; LAPATINIB; NAVELBINE; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOOT PAIN; HEART EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; METASTATIC BREAST CANCER; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; POPULATION; PRIORITY JOURNAL; SERUM SICKNESS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMISTRY; METASTASIS; MIDDLE AGED; PATHOLOGY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETREATMENT; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; HUMANS; MAYTANSINE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETREATMENT; RETROSPECTIVE STUDIES; TRASTUZUMAB;

EID: 84990026687     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.3624     Document Type: Article

References (25)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
2. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
5. Lewis Phillips GD, Li G, Dugger DL, et al: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290, 2008
6. Amiri-Kordestani L, Blumenthal GM, Xu QC, et al: FDA approval: Ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 20:4436-4441, 2014
7. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
8. Blumenthal GM, Scher NS, Cortazar P, et al: First FDA approval of dual anti-HER2 regimen: Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res 19:4911-4916, 2013
9. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
10. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
11. Schneeweiss A, Chia S, Hickish T, et al: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278-2284, 2013
12. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
13. Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013
14. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
15. Ellis PA, Barrios CH, Eiermann W, et al: Phase III, randomized study of trastuzumab emtansine (T-DMI) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.American Society of Clinical Oncology Annual Meeting, May 29-June 2, 2015, Chicago, IL
16. Hurvitz SA, Dirix L, Kocsis J, et al: Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31:1157-1163, 2013
17. Krop IE, Kim SB, González-Martín A, et al: Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial. Lancet Oncol 15:689-699, 2014
18. Burris HA III, Rugo HS, Vukelja SJ, et al: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405, 2011
19. Krop IE, LoRusso P, Miller KD, et al: A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30:3234-3241, 2012
20. Sant M, Allemani C, Berrino F, et al: Breast carcinoma survival in Europe and the United States. Cancer 100:715-722, 2004
21. Murthy RK, Varma A, Mishra P, et al: Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120:1932-1938, 2014
22. Tripathy D, Brufsky A, Cobleigh M, et al: Increasing proportion of de novo compared with recurrent HER2-positive metastatic breast cancer: Early results from the systemic therapies for HER2-positive metastatic breast cancer registry study. San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2014
23. Yardley DA, Kaufman PA, Brufsky A, et al: Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat 145:725-734, 2014
24. Vaz-Luis I, Seah D, Olson EM, et al: Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: A retrospective cohort study. Clin Breast Cancer 13:254-263, 2013
25. Rossi V, Nolè F, Redana S, et al: Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. Breast 23:44-49, 2014